Biobohemia's Pipeline

Biobohemia's strategy is based on development and rapid clinical entry of SANTAVAC cancer vaccines based on antiangiogenic essences, demonstration of clinical safety and efficacy of this approach, and follow-on development of additional immunotherapeutic candidates. This strategy will allow for the leveraging of initial development efforts of the most advanced candidate to allow expedient transition for the other candidates. Biobohemia's therapeutic pipeline includes technologically distinct candidate products:

• Therapeutic SANTAVAC¹⁵ DC is an antiangiogenic SANTAVAC¹⁵-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which primary culture of allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
• Preventive SANTAVAC²⁵ DC is an antiangiogenic SANTAVAC²⁵-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which commercially available allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
• Therapeutic SANTAVAC¹⁵ vaccine is a peptide vaccine composed of allogeneic SANTAVAC¹⁵ mixed with adjuvant.
• Preventive SANTAVAC²⁵ vaccine is a peptide vaccine composed of allogeneic SANTAVAC²⁵ mixed with adjuvant.

In addition to encompassing technologically distinct candidates, the therapeutic pipeline encompasses separate formulations that can also target different types of cancer. Notwithstanding, the development programs are all highly focused on one target: antigen compositions developed by antigenic essence technology and intended for the development of cancer vaccines against solid tumors. This circumstance simplifies the overall R&D efforts and creates synergy among all of the programs, allowing the programs and their associated achievements to leverage each other. The development programs may be corrected according to the results of animal testing.